Nephrology News
First-line Pazopanib May Improve Outcomes in Advanced RCC
Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/